Royal Bank of Canada started coverage on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a report published on Wednesday, FinViz reports. The brokerage issued a sector perform rating and a $7.00 target price on the stock.

Several other equities research analysts have also commented on the stock. SVB Leerink restated a market perform rating on shares of Endo International in a report on Monday, February 8th. Zacks Investment Research lowered shares of Endo International from a buy rating to a sell rating and set a $7.50 price objective for the company. in a research note on Tuesday, January 12th. Piper Sandler boosted their price objective on shares of Endo International from $6.00 to $12.00 and gave the stock an overweight rating in a research note on Monday, January 4th. Citigroup cut their price target on shares of Endo International from $11.00 to $10.00 in a research note on Thursday, March 4th. Finally, Barclays upped their price objective on shares of Endo International from $6.00 to $7.00 and gave the company an equal weight rating in a report on Monday, March 8th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $7.64.

Endo International stock traded down $0.67 during trading hours on Wednesday, hitting $6.09. The company had a trading volume of 153,670 shares, compared to its average volume of 3,977,550. The firm has a market cap of $1.40 billion, a P/E ratio of -9.01 and a beta of 1.41. Endo International has a 1 year low of $2.71 and a 1 year high of $10.89. The company has a 50-day moving average price of $8.22 and a two-hundred day moving average price of $6.45.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, February 25th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.27. The company had revenue of $760.22 million during the quarter, compared to analysts’ expectations of $653.83 million. Endo International had a negative net margin of 5.30% and a negative return on equity of 85.80%. During the same period in the previous year, the company earned $0.74 EPS. Research analysts forecast that Endo International will post 2.55 EPS for the current fiscal year.

In other Endo International news, Director Shane Cooke sold 17,290 shares of the firm’s stock in a transaction that occurred on Monday, March 15th. The shares were sold at an average price of $8.65, for a total transaction of $149,558.50. Following the sale, the director now owns 97,104 shares of the company’s stock, valued at $839,949.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.50% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in ENDP. Vantage Consulting Group Inc acquired a new position in Endo International in the 4th quarter valued at $89,000. IFP Advisors Inc purchased a new stake in shares of Endo International during the 4th quarter worth $111,000. Nisa Investment Advisors LLC boosted its position in shares of Endo International by 131.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 17,700 shares of the company’s stock worth $127,000 after purchasing an additional 10,050 shares in the last quarter. Everence Capital Management Inc. purchased a new stake in shares of Endo International during the 1st quarter worth $235,000. Finally, Alpha Paradigm Partners LLC purchased a new stake in shares of Endo International during the 4th quarter worth $272,000. 79.98% of the stock is currently owned by institutional investors.

About Endo International

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; TESTOPEL, an implantable pellet indicated for TRT in conditions; EDEX to treat erectile dysfunction; and LIDODERM a topical patch product containing lidocaine.

Featured Article: What does a dividend yield signify to investors?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.